BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 19, 2024
Home
»
Newsletters
» BioWorld Asia
BioWorld Asia
July 11, 2007
View Archived Issues
Silence Signs AstraZeneca To $400M Respiratory Drug Deal
In its largest deal to date, RNAi firm Silence Therapeutics plc is partnering with AstraZeneca plc in a potential £200 million (US$400 million) to develop drugs against respiratory disease targets. (BioWorld International)
Read More
CureVac Receives €13M To Boost mRNA Cancer Vaccines
No Abstract
Read More
One Bad SNP Carries Variant Linked To Bowel Cancer Risk
Read More
Neuropharm Gets Patients' Group Support For Autism Program
Read More
Other News To Note
Read More
GW Expands Cannabis Franchise Into CNS, Oncology Indications
Read More
EU Prediction: Europe's Biotech Future Will Depend On Change
Read More
To-BBB Raises $5.4 Million For CNS Drug Delivery
Read More